
SS-31
SS-31 and Forzinity: the U.S. accelerated approval is specific to muscle strength in Barth syndrome. Read the population, endpoint and confirmation limits.
About:
Elamipretide binds cardiolipin. Its U.S. prescription product Forzinity has accelerated approval for a specified Barth syndrome population, not a general energy or healthy-aging indication.
Approval scope checked October 26, 2026: Forzinity is approved for a specific Barth syndrome population.
What is SS-31?
SS-31 is also known as elamipretide. In the United States, Forzinity (elamipretide) injection has accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. The approval is based on knee extensor muscle strength, an intermediate endpoint; confirmation of clinical benefit is required. This product-specific approval does not establish benefit for general energy, healthy aging or research-market SS-31 vials.
The prescribing information describes a randomized, placebo-controlled crossover study and an open-label extension. The randomized comparison did not show superiority on walking distance or fatigue. The later knee-strength observations do not make those primary endpoints positive.
Sources and limits: FDA announced the approval on September 19, 2025. The prescribing information is revised September 2025; the DailyMed page was updated December 10, 2025. These older official records support this specific clarification. This is not a new trial result or a complete clinical review of the historical claims and grades elsewhere on the page. [1] FDA approval announcement | [2] Forzinity prescribing information
This clarification is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It is not medical advice or a recommendation to use a medicine.
What does this peptide do?
Backed by human trial data, narrower than the strongest evidence. Research focuses on mitochondrial function.

Mitochondrial function
Binds cardiolipin; developed clinically as elamipretide.
Evidence grade
BHighest evidence grade among the graded claims: B. Grades reflect study strength, not benefit.
What are the benefits and side effects of this peptide
What research says it may help with
- Forzinity has U.S. accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.
- Knee extensor strength is an intermediate endpoint; a confirmatory trial must establish clinical benefit.
- Approval of the prescription product does not validate research-market vials or general healthy-aging claims.
Who should avoid it
- People who are pregnant or breastfeeding
- Anyone substituting research-market vials for the prescription product Forzinity
- Known hypersensitivity to the compound
See the safety section. Absence of a flag is not evidence of safety.
A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.

How to store this peptide
The clinical product is a regulated pharmaceutical. Research-market vials are typically lyophilized powder; reconstituted solutions are perishable, need refrigeration, and require clean handling.
Lyophilized storage
Refrigerate at 2–8 °C in the original carton. Do not freeze.
Reconstituted storage
Once in use, may be kept below 30 °C for the period stated on the product label.
Storage Handling
Protect from light. Do not use if it has been frozen.
Related research
Related research is coming soon for this peptide.


